Article
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.
Blood advances - 14 Dec 2021
Tiong Ing S, Dillon Richard, Ivey Adam, Kuzich James A, Thiagarajah Nisha, Sharplin Kirsty M, Kok Chung Hoow, Tedjaseputra Aditya, Rowland James P, Grove Carolyn S, Abro Emad, Shortt Jake, Hiwase Devendra K, Bajel Ashish, Potter Nicola E, Smith Matthew L, Hemmaway Claire J, Thomas Abin, Gilkes Amanda F, Russell Nigel H, Wei Andrew H
Abstract excerpt
Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level <1% to 2% with a <1-log change between any 2 positive samples collected after the end of treatment (EOT). Because the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.